Cancer Outcomes and Services Dataset What is COSD? Implications for Providers and Networks.

Slides:



Advertisements
Similar presentations
Cancer Registration and Health Service Regulation Dr Jenifer A E Smith.
Advertisements

UK Clinical Research Network (UKCRN) UK Clinical Research Network Maxine Stead PhD UKCRN Assistant Director – Clinical Trials.
South West Specialised Commissioning Group Selena Blake – Senior Commissioning Manager / TYA Programme Manager South West Specialised Commissioning Group.
Local Improvement following National Clinical Audit The View from a National Clinical Audit Provider – the Health & Social Care Information Centre.
Northern & Yorkshire Cancer Registry & Information Service NHS UKACR Conference 30 September How useful is the Cancer Waiting Times (CWT) dataset.
National Prostate Cancer Audit Julie Nossiter, Project Manager Clinical Effectiveness Unit – Royal College of Surgeons.
NPCA data submission and reporting
Research and Development Department A Quick Guide to Using EDGE v2 for Researchers Version 1.2 – 23 February
National Prostate Cancer Audit Heather Payne, NPCA Oncological Clinical Lead Consultant Clinical Oncologist, UCL.
Chameleon Information Management Services Ltd NPCA Update from InfoFlex Sarah Waters Director of New Business.
March 2002 Outcomes in thyroid cancer: what factors are important? Information Projects Team Outcomes in thyroid cancer: what factors are important? NYCRIS.
Trust Cancer Lead Clinician
National Cancer Registry Luxembourg EUROCHIP-3 Meeting Ispra, 27 th February 2012 Olivier Collignon, PhD, Sophie Couffignal, MD, CRP-Santé.
The LCA: Implementing a Quality Assurance and Informatics Strategy to Enhance Cancer Care Dr Shelley Dolan LCA Clinical Director.
The National Cancer Intelligence Network An overview Professor David Forman Professor of Cancer Epidemiology, University of Leeds NCIN – Lead for Information.
Children and Young People Improving Outcomes Guidance  Key aims of guidance and age specific requirements  Designation of Principal Treatment Centres.
ISB Notice and preparing for the implementation of the new IAPT Data Standard Shaun Crowe Mental Health, Employment and IAPT Mental Health Collaborative.
Evaluation of Electronic Radiotherapy Data for Quality Checking Cancer Registry Data Colin Fox (NICR) Richard Middleton (NICR) Denise Lynd (BCH – COIS)
Kent & Medway Cancer Network Thames Cancer Registry Cancer Registration Dataset Pilot Nigel Brook.
National Bowel Cancer Audit Clinical Audit Platform How to Register, Submit and View Reports CAP:
National Oesophago–Gastric Cancer Audit Key Findings from 2014 Annual Report and Progress Report Georgina Chadwick Clinical Research Fellow.
Suppliers Forum Dave Roberts – Programme Head non-acute care.
National Oesophago-Gastric Cancer Audit Clinical Audit Platform How to Register, Submit and View Reports CAP: |
Radiotherapy Data Collection Helen Forbes National Cancer Services Analysis Team.
Submission, Reporting & Sign-off Process Kirsty Anderson Principal Information Analyst.
ENT, OMF and Head and Neck Cancer Services Review Mary Hutton 27 th January 2011.
The Health Roundtable Improving data collection rates, while improving quality Presenter: Sandra Avery Liverpool Innovation Poster Session HRT1215 – Innovation.
Chester Ellesmere Port & Neston Rural Making sure you get the healthcare you need West Cheshire CCG Strategy Dr Andy McAlavey Medical Director West Cheshire.
FGM – THE ENHANCED DATASET DR EMMA TUKMACHI LEAD GP FOR SAFEGUARDING CHILDREN IN TOWER HAMLETS.
Cancer Mortality Target Measuring and Monitoring at a National Level Jennifer Benjamin, Department of Health Kathy Elliott, National Cancer Action Team.
BETTER CANCER CARE A Discussion Elizabeth Porterfield Head, NHS National Planning Team SGHD.
Cancer Outcomes and Services Dataset Linda Wintersgill Information & Audit Manager, NECN.
Croydon Health Services Paperlite GP Referrals – Using the Service Provider Functionality within ICE Croydon Healthcare NHS Trust is using the Service.
Monitoring the National Cancer Standards for dummies…… ……….by dummies Louise Carrington. Programme Co-ordinator CSCG Andrew Graham. HSW.
LUCADA Jacqueline Brown Cancer Services Manager North Tees & Hartlepool Trust.
100k Genomes Project Programme of Whole Genome Sequencing, part of UK Life Sciences Strategy Aim to sequence 100,000 genomes from patients with cancer.
Cancer Information Framework Initial feedback on NWCN LUCADA submission 2006 data Wednesday 20 th February, 2008 Linda Roberts, Cancer Information Specialist,
Carlos Rocha Registry Manager National Cancer Registration Service (South West) West Dean Registration Improvement of Non-Melanoma skin cancer.
National Cancer Survivorship Initiative 2010 Update.
What data are available, and how are they accessed?
National Cancer Intelligence Network What data are available, and how are they accessed? Cancer Roadshow (London) 13 th April 2015 Vivian Mak, Information.
Facilitating tissue collection for translational research Jane Rogan Business Manager.
The Cancer Registry of Norway Jan F Nygård Head of the IT-department.
What data are collected? How, and who by? Karen Graham and Barry Plewa.
NCIN Roadshow: Cancer Data NCIN - Cancer Data Roadshow Public Health England | 2015 Elsita Payne Head of Registration – East Midlands and North West Branches.
South West Public Health Observatory South West Regional Public Health Group Opportunities for future analysis by SWPHO Sean McPhail South West Public.
Where can I find data on cancer? Victoria H Coupland London Knowledge and Intelligence Team 20 February 2014.
Tumour Streams Eleanor Whitehead CCN Project Manager.
Profession Specific Audit for Stroke Care Initiated by Intercollegiate Stroke Working Party (ICSWP) National Sentinel Audit (1998….2006) RCP National Clinical.
What does the cancer intelligence landscape look like now? Dr Mick Peake Clinical Lead, National Cancer Intelligence Network.
What data are available, and how are they accessed?
Faster Cancer Treatment (FCT) - Improving quality of care across the patient cancer pathway Update Aug 2012.
Private and confidential Community Pharmacy Future Four-or-more medicines support service Update on progress and next steps Approved18 th June 2012 This.
What data are collected? How, and who by?. It’s complicated… ONS data.
The Quality Surveillance Team / Programme
Dr. Kęstutis Adamonis, Dr. Romanas Zykus,
SWAG Cancer Alliance Update
Recognition and Referral of Suspected cancer NICE NG12 – 2Week Wait
West of England Genomic Medicine Centre: Our Progress to Date
Somerset Cancer Register
National Lung Cancer Audit
Somerset Cancer Register
Segmented analysis of the lung cancer median pathway from referral to treatment: This work was carried out in partnership between the Transforming.
Hannah Marder Cancer Manager UH Bristol
Somerset Cancer Register
Chemotherapy Services in England: Ensuring quality and safety
Quality Surveillance Programme
Breast Cancer SSG 14th November
Living With & Beyond Cancer (Personalised Care): SWAG Colorectal CAG Update 5th June 2019 Catherine Neck, Macmillan Cancer Rehabilitation/ LWBC Lead On.
NHS Long Term Plan: Rapid Diagnostic Centres (RDC) The SWAG Approach
Presentation transcript:

Cancer Outcomes and Services Dataset What is COSD? Implications for Providers and Networks

...Cancer registration and careful monitoring of treatment and outcomes are essential... Calman-Hine “Our aspiration is that England should achieve cancer outcomes which are comparable with the best in the world” Improving Outcomes: a Strategy for Cancer, years ago....

Why are we doing this – the impact of information? 31 Days - CWT

Why are we doing this – newer Information? Routes to Diagnosis

There is a wealth of information There are 100s of aspects that must be taken into account when making decisions about a Clinical Service Survival trends per cancer type and PCT Activity per admission type and PCT Drug budget per indication and network and PCT Excess bed- days per cancer type, trust and PCT # TWR with cancer diagnosis Place of death per PCT of patient and trust

 The new national cancer dataset  Incorporates previous cancer registration dataset  Cancer Outcomes and Services  Aligned with patient management  Proposed and supported by clinicians  Updated and aligned with other datasets  Clarified definitions of data items, codes and values  Specifies Provider submissions  Compiled by registries from Providers and other sources What is COSD?

Cancer Outcomes and Services Dataset COSD - Structure CENTRAL NERVOUS SYSTEM COLORECTAL CHILDREN,TEENAGERS, YOUNG ADULTS GYNAECOLOGY HAEMATOLOGY HEAD & NECKLUNG SARCOMA SKIN UPPER GI UROLOGY CORE - CANCER REGISTRATION Demographics/Referral/Diagnostics/Diagnosis/Care Plan/Treatment BREAST CANCER WAITS Site specific Clinical and Path Patient pathway referral to treatment

 Complete patient pathway  Referral details for all cases  All treatments  Includes palliative and supportive care  New core data items including  TNM Edition Number  Involvement of Clinical Nurse Specialist  Duration of symptoms  Mandatory for Children,Teenagers,Young Adults (CTYA), Optional for others  Year/Month/Day as appropriate or available  All registerable conditions including  in situ bladder, in situ melanoma, benign brain tumours What’s different about COSD? (1)

 Site specific data  Key site specific clinical items – patient management  Site specific stage  Stage components of RCPath datasets  Includes recurrences  Breast cancers to start with  New record including referral information What’s different about COSD? (2)

COSD Dataset Pathology PAS National Feeds – datasets and other sources e.g. CWT, RTDS, SACT, (ONS) MDT Radiology Compilation into a single dataset (assembled by Registries – not by Providers)

 Multiple Trust systems (MDT, PAS, Path, RIS)  Separate files for MDT, PAS, Path, RIS  Compiled by registries  Method of transmission  Agreed with registries  Secure transmission - nhs.net  Aim towards XML  Path data extracted from path reports by registries  Complete Data Transfer Agreement  Minimising duplication of data flows What does this mean for you? (Informatics 1)

 XML Action Plan  to develop XML  Support for in house developers  Interim arrangements with Registry What does this mean for you? (Informatics 2)

 Monthly submission  Current cancer registry feeds expanded to include COSD items  25 working days after diagnosis or treatment  Send updates as applicable  Aim for three months to complete initial record (to first treatment)  Final updates to first treatment within 6 months  Further treatments - submit 25 working days after treatment  How to collect in “real time” ?  Clinical ownership/sign off for  MDT extract  PAS extract  Path extract  RIS extract What does this mean for you?

 Resources  Point of care recording  Clinical sign off/Ownership  Review and revise processes  Inter Provider pathways  Network wide implementation  Data collection agreements  Alignment with national audits  Differences identified  Move towards integrated submission Key sources – MDT System

 Existing extracts continue  Path items may also be recorded in MDT system  Can send from both systems  Free Text Reports  Data items extracted by registries  Direction of travel  Structured reporting  Clinical oversight  Summary feedback reports Key Sources – Pathology System

 Existing extract  Use SUS/CDS/PbR return  Check COSD data items included  Discuss with regional registry  Process for Clinical oversight  Feedback reports Key sources – PAS

 How to identify cases  Can system identify cancer cases automatically  Can CWT be used to identify reports for cancer investigations  Identified by registries to request reports for specified cancer  Remote access to RIS for registries  IEP – future option?  Use of Diagnostic Imaging Dataset (DID)?  Free Text reports  Data items extracted by registries  Clinical oversight  Summary feedback reports  Radiology items recorded in MDT system  Can send from both systems Key sources – Radiology System

GAP Analysis – Conformance Checklist

Support

 Included in National Contract  Information Standard  Possible financial penalty  Simple criteria  Monthly feedback to Providers (raw data)  e.g. data submitted on time?  Staging data completeness  Quarterly and annual feedback to follow (processed data)  Potential Escalation process  Informal discussions  Notification to CEO  Formal notification to commissioners  NHS Commissioning Board Conformance

Implementation Timetable July 12 ISN issued Jan 13 CORE and SITE SPECIFIC STAGE July 13 SITE SPECIFIC CLINICAL Jan 14 SITE SPECIFIC PATHOLOGY Jan 15 FULL COSD DATASET submitted in XML ISB Approval June 12

Future Direction for Cancer Registries What is happening at the cancer registries and how it will support Trusts?

 Single England wide system  Cancer Outcomes and Services Dataset compliant  Facilitates rapid processing of multiple local and all national data sources  Common standards and processes including data quality  Provides rapid and direct feedback of data to clinical teams to enhance data quality  Support for (near) real-time surveillance, cancer audit and analysis  Datasets available for external analysis and research Local data collection at MDTs is key to success National Cancer Registration Service

Data sources - patient-level data Cancer Waiting Times Chemotherapy Dataset (SACT) Radiotherapy Data (RTDS) National PET- CT imaging Hospital Episode Statistics (HES) ONS - Cancer and non- cancer deaths Cancer screening programmes - Bowel, Cervix and Breast Patient Administration Systems Pathology full-text reports Local imaging systems Data from MDT software systems Local clinical data systems CRUK Stratified Medicine (Sept 2011) Recurrent/Meta static Breast Audit Pilot National Feeds (inc COSD indirect) Local Feeds (COSD direct) National Pilots Encore National cancer audits - Lung, Head and Neck, Upper GI and Colorectal

S251 NHS Act exemption All cancer registries covered – one annual application Annual renewal through National Information Governance Board (NIGB) and corresponding statutory instrument Caldicott Guardian sign-off required to allow transfer of data to and from organisations existing signoff covers COSD Information Governance (1)

 Data Protection Act  All cancer registries are registered under the DPA.  Fair processing notices, including rights to withdraw consent, are provided through the UKACR Patient Information Leaflet (under revision)  Latest version of leaflet available from: Information Governance (2)

 Monthly Conformance Report  Extract files received, number of cases, timeliness etc  Data Quality  Initial completeness eg NHS number, stage, performance status, diagnosis  Summary Information Indicators  Eg % histologically verified, RCPath data item completeness  Clinical and Performance Indicators  NICE Quality Standards etc  Eg % lung resections  % breast conserving surgery with no Radiotherapy Feedback for Providers and Clinical Teams

Proposed Feedback Timetable July 12 ISN issued Jan 13 CORE and SITE SPECIFIC STAGE July 13 SITE SPECIFIC CLINICAL Jan 14 SITE SPECIFIC PATHOLOGY Jan 15 FULL COSD DATASET submitted in XML First feedback reports ~ Mar 13 First submission - 7 th Mar 13 Standard clinical feedback reports ~ Mar 14 Summary reports ~ Sept 13

Future Feedback?

 A single cancer registration system (ENCORE) for England  COSD compliant  Routine, timely feedback  Improved registry/clinical partnership working  Provide powerful data for local, national and international analysis The Future